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Abstract objective Multidrug-resistant tuberculosis (MDR-TB) is an emerging public health problem in
Ethiopia. The aim of this study was to assess MDR-TB treatment outcomes and determine predictors
of poor treatment outcomes in north-west Ethiopia.
methods A retrospective cohort study was conducted using all MDR-TB patients who were
enrolled at Gondar University Hospital since the establishment of the MDR-TB programme in 2010.
A Cox proportional hazard model was used to identify the predictors of time to poor treatment
outcomes, which were defined as death or treatment failure.
results Of the 242 patients who had complete records, 131 (54%) were cured, 23 (9%) completed
treatment, 31 (13%) died, four (2%) experienced treatment failure, 27 (11%) were lost to follow-up,
six (2%) transferred out, and 20 (8%) were still on treatment at the time of analysis. The overall
cumulative probability survival of the patients at the end of treatment (which was 24 months in
duration) was 80% (95% CI: 70%, 87%). The proportion of patients with poor treatment outcomes
increased over time from 6% per person-year (PY) during 2010–2012, to 12% per PY during 2013–
2015. The independent predictors of time to poor treatment outcome were being anaemic
[AHR = 4.2; 95% CI: 1.1, 15.9] and being a farmer [AHR = 2.2; 95% CI: 1.0, 4.9].
conclusions Overall, in north-west Ethiopia, the MDR-TB treatment success rate was high.
However, poor treatment outcomes have gradually increased since 2012. Being a farmer and being
anaemic were associated with poor treatment outcomes. It would be beneficial to assess other risk
factors that might affect treatment outcomes such as co-infection with malaria, poverty and other
socio-economic and biological risk factors.
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Introduction
Multidrug-resistant tuberculosis (MDR-TB) is a major
public health problem globally and is an obstacle for
national TB control programmes [1]. MDR-TB is defined
as TB that is resistant to at least the two most effective
first-line anti-TB drugs, isoniazid (INH) and rifampicin
(RIF) [1]. According to the WHO 2015 Global Tubercu-
losis Report, 480 000 MDR-TB cases were estimated to
be diagnosed globally, and of these, 190 000 (39.5%)
died as a result of it in 2014 [2]. Furthermore, WHO
estimated that only 25.6% of MDR-TB cases were diag-
nosed and only 23.1% of cases received access to MDR-
TB treatment globally, and of those who had received
MDR-TB treatment, only 50% were successfully treated
[3, 4].
Ethiopia is a high TB-burden country and reports
approximately 140 000 cases of TB each year [5]. The
MDR-TB burden in Ethiopia is not well known, except
for estimates based on the first-round drug resistance
survey (DRS) conducted in 2003–2005 which showed
that 1.6% and 11.8% of new and previously treated TB
cases had MDR-TB, respectively [6, 7]. MDR-TB was
reported in Ethiopia 30 years ago in a hospital-based
study [8], and since this time, the estimated number of
patients with MDR-TB has increased exponentially.
Whereas 145 MDR-TB cases were reported in 2007, this
number had risen to 558 in 2013 [2]. Ethiopia ranks
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17th in the list of the world’s 27 high-burden countries
for multidrug-resistant and extensive drug-resistant tuber-
culosis (M(X) DR-TB), with more than 2200 estimated
MDR-TB patients every year [2].
As a result, the Ethiopian government has identified
MDR-TB as one of the country’s priority public health
problems. In 2009, the government initiated a national
MDR-TB treatment programme, with two designated
MDR-TB treatment centres: one in Gondar University
Hospital, Gondar, and the other at St. Peter’s Tuberculo-
sis Specialized Hospital, Addis Ababa. Since this time, 10
additional MDR-TB treatment centres have opened in the
country [5]. Acid-fast bacillus (AFB) microscopy is widely
used across the country for TB diagnostic and treatment
follow-up services. However, culture and drug suscepti-
bility testing (DST) is only available in national and
regional laboratory centres and requires referral of either
samples or patients. Phenotypic DST and line-probe assay
(i.e. Geno Type MTBDRplus V.2.0, HAIN Life, Science,
Nehren, Germany) are used at national and regional ref-
erence laboratories to identify MDR-TB cases. Patients
diagnosed with MDR-TB are eligible to get treatment ser-
vice free of charge [5, 9].
Improving MDR-TB treatment outcomes is one of the
five priority actions recommended by WHO to address
the global MDR-TB crisis [3], with a target of 75% treat-
ment success by the end of 2015 [10]. Many countries
currently fall short of this ambitious target. The predic-
tors of favourable treatment outcomes for people with
MDR-TB vary according to the context [11–13]. There
are few studies on MDR-TB treatment outcomes in
resource-constrained settings and in high MDR-TB-bur-
den countries [14, 15]. The purpose of this study was to
assess MDR-TB treatment outcomes, predictors of time
to poor MDR-TB treatment outcome and temporal
trends in MDR-TB treatment outcomes among patients
who were enrolled in Gondar University Hospital MDR-
TB Treatment Centre since its establishment in September
2010.
Methods
Study setting and participants
A retrospective cohort study was conducted at Gondar
University Hospital among MDR-TB patients who regis-
tered at the MDR-TB treatment centre, between Septem-
ber 2010 and August 2015. Gondar University Hospital
is the oldest hospital in the country and is located in
north-west Ethiopia. It provides healthcare services for a
catchment population of approximately 5 million people
in North Gondar and the neighbouring region. Patients
are enrolled in the MDR-TB treatment centre if they have
[1] bacteriological evidence of rifampicin resistance (RR),
determined by culture; [2] bacteriological evidence of
MDR-TB, determined by a line-probe assay (i.e. Geno
Type MTBDRplus V.2.o, HAIN Life, Science), Gene
Xpert or conventional drug susceptibility testing (DST);
or [3] clinical evidence of MDR-TB based on multiple
treatment failures, or a history of contact with someone
with MDR-TB. All patients enrolled at the MDR-TB
treatment centre are eligible for treatment [9].
Treatment regimen
At the hospital, MDR-TB treatment is prescribed based
on the recommendations of the Ethiopian Federal Min-
istry of Health National MDR-TB Guideline, which is
based on recommendations from WHO guidelines [16].
All newly diagnosed MDR-TB patients receive a stan-
dardised regimen of first- and second-line TB drugs that
consists of an 8-month intensive phase with a combina-
tion of pyrazinamide (Z), capreomycin (CM), levofloxa-
cin (Lfx) and prothionamide (Pto) or ethionamide (Eto)
and cycloserine (Cs), a 12-month continuation phase with
a combination of pyrazinamide (Z), levofloxacin (Lfx),
prothionamide (Pto) or ethionamide (Eto), and cycloser-
ine (Cs) [9]. However, certain groups of MDR-TB
patients cannot receive the standardised regimen, requir-
ing either a modification of the regimen or dose adjust-
ment [9]. These groups include pregnant women,
children, patients with comorbidities such as chronic
renal dysfunction, HIV or liver disease, patients who
report household contact with other rifampicin-resistant
(RR)/MDR or XDR-TB patients, and patients who have
a history of prior exposure to second-line TB drugs [9].
Data collection
Data were extracted from patients’ MDR-TB registration
books and medical records. The registration book con-
tained a number of variables including socio-demographic
characteristics (age, sex, residence, marital status, educa-
tional status, occupation, religion, treatment supporter),
clinical variables (HIV status and other comorbidities,
site of TB disease, number of previous TB treatments, ini-
tial MDR-TB regimen, initial regimen change, vitamin B6
supplementation, initial sputum and culture result,
adverse drug effects, height and weight) and laboratory
profile (haemoglobin (Hgb), alanine transaminase (ALT),
aspartate transaminase (AST), creatinine, serum potas-
sium (K) level and white blood cell (WBC) count). Data
were collected by four healthcare officers who were
working in the MDR-TB treatment centre, and who were
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trained in study procedures. The collected data from the
registration books were cross-checked with the medical
records of the patients by the investigators.
Treatment outcomes
MDR-TB treatment outcomes were assigned as per the
definitions in the Ethiopian national TB guidelines, which
have been adopted wholly from the WHO definitions and
reporting framework for TB guidelines as cured, treat-
ment completed, treatment failed, died, lost to follow-up
and not evaluated [9, 17]. A patient was classified as
cured if the patient completed treatment without evidence
of treatment failure and if they had three or more consec-
utive negative cultures taken at least 30 days apart, after
the intensive phase. Treatment completion was defined as
completed treatment, without evidence of failure but with
no record that three or more consecutive cultures taken
at least 30 days apart were negative after the intensive
phase. Treatment failure was defined as treatment termi-
nated or a need for permanent regimen change of at least
two anti-TB drugs because of a lack of conversion by the
end of the intensive phase, or bacteriological reversion in
the continuation phase after conversion to negative after
intensive phase, or evidence of additional acquired resis-
tance to fluoroquinolones or second-line injectable drugs,
or adverse drug reactions. Lost to follow-up referred to
interruption of a patient’s treatment for 2 consecutive
months or more. Death referred to death for any reason
during the course of treatment. A patient for whom no
treatment outcome was assigned either due to being
transferred out to other facility or still on treatment was
classified as not evaluated.
In this study, treatment success was defined as the pro-
portion of all patients who were taking their MDR-TB
treatment for the recommended duration and who were
declared as either cured or completed (excluding non-
evaluated patients). A poor treatment outcome was
defined as the proportion of all patients who died or
failed treatment excluding those who were not evaluated.
The outcome of interest (events) for the survival analy-
sis was ‘death’ or ‘treatment failure’, whichever came
first. Combined, these two events represented poor treat-
ment outcomes. Patients were considered as censored if
they had the TB treatment outcome of cured, completed,
transferred out or lost to follow-up or were still on treat-
ment at the end of the study. To include the censored
observations in the analysis, we calculated a censored
survival time from the start date of treatment (T0) to [1]
the date of data collection for patients still on treatment,
[2] the last known date of observation for the patients
lost to follow-up or transferred out and [3] the date
declaration of cure or treatment completion. The follow-
up time (FT) was the time from T0 to the date of event
or censoring. The time to event survival time (ST) was
the time from T0 to the date when the patient experi-
enced an event (T1), in this case death or treatment fail-
ure. The treatment outcome was coded as 1 if the event
occurred at time Ti and 0 if the event had not occurred
(i.e. if it was censored) at time (Ti). The overall survival
of the patients was analysed and measured from T0 to
the date of failure or death, whichever came first (Fig-
ure 1). Based on the WHO definition, patients were con-
sidered as anaemic if their haemoglobin concentration
was <120 g/l [18].
Data analysis
Data were checked for completeness and entered into a
form designed in EPI Info version 3.5.3. Data were then
exported to STATA version 14.1 [19] for analysis. Cate-
gorical variables were summarised by counts and per-
centages, and the differences between groups were
compared using Pearson’s chi-square (v2) or Fisher’s
exact test, where appropriate. Normally distributed con-
tinuous variables were summarised by their mean and
standard deviation (SD), and we used a two-sample
independent t-test to compare the mean values. Non-
normally distributed continuous variables were sum-
marised by their median and interquartile range (IQR),
and we used a Wilcoxon rank-sum test to compare the
median values. A Kaplan–Meier (KM) curve was used
to estimate the cumulative survival probability and the
median ‘survival’ time of the patients. The log-rank test
was used to compare the survival experience of two or
more groups of the study subjects. A bivariate Cox pro-
portional hazard model was first fitted, and the variables
significant at P-value <0.1 in the bivariate analysis were
used in the final multivariable Cox proportional hazard
model. Crude and adjusted hazard ratios were calculated
to measure time to poor treatment outcomes. The over-
all adequacy of the general predictive power of the
model was measured using Harrell’s c index (note: we
observed that the c index was 0.7612, which did achieve
the 0.70 mark for acceptable discrimination for prognos-
tic model). The Cox proportional hazard assumption
was also examined for each covariate and globally using
a formal significance test based on the unscaled and
scaled Schoenfeld residuals. It was observed that the
proportional hazard assumption was justified, because
the test was not significant (P = 0.46). In addition, a
graphical assessment of proportional hazards was made
using log–log survival curves. Data were missing for
some patients for height, weight, ALT and AST and;
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missing values were imputed as the sex-specific median
for these variables.
Ethics approval
Ethical clearance was obtained from the Institutional
Review Board of the University of Gondar and from the
Australian National University Human Research Ethics
Committee. The University of Gondar Hospital provided
permission to access the data. As this study used sec-




A total of 282 patients were registered and commenced
on MDR-TB treatment between 2010 and 2015. Of
these, 242 (86%) MDR-TB patients had complete records
and were included in the analysis. Half of the patients
(123, 50%) were from North Gondar zone, and two-
thirds (61%) of the patients were male. The median age
of patients was 30 years (range 3–73 years), and patients
had low average monthly income (median income 997
Ethiopian Birr, IQR 600–997) (Table 1).
Clinical characteristics
Almost all patients had pulmonary TB 227 (94%) with
positive sputum smear results for 194 (80%) and a posi-
tive culture result for 131 (54%). There were 13 cases of
rifampicin mono-resistance (4.6%), and there were two
cases of XDR-TB (0.7%), who both died. The majority
of patients (225, 93%) had a history of TB treatment,
and the median number of previous TB treatment was 2
(IQR: 2–3). The initial regimens were modified for 15
(6%) of the patients. The reasons for these modifications
are not well documented. Psychosis and treatment failure
were reported as the most common side effects and rea-
sons for regimen change. At the commencement of treat-
ment, the majority of patients (174, 72%) were
underweight (BMI < 18.5 kg/m2); the mean baseline BMI
of the event category was 16.2 km/m2  2.7 and of the
censored category was 17.3 km/m2  2.6, (P-
value = 0.02). Similarly, the mean haemoglobin level at
baseline for the event category was 12.7  6.4 and for
the censored category was 10.6  2.73) (P-value = 0.07)
(Table 2).
Treatment outcomes
Of the 242 MDR-TB patients, 131 (54%) were cured, 23
(10%) completed treatment, 31 (13%) died, and four
(2%) had treatment failure (Table 3). Treatment outcome
was assessed for 189 (78%) patients, and the proportion
of MDR-TB patients who successfully completed treat-
ment among these patients was 154 (81%). The treat-
ment outcome was not evaluated for 53 (22%) patients
because 20 (8%) were still on treatment, six (2%) trans-
ferred out to another MDR-TB treatment centre and 27
(11%) were lost to follow-up (Table 3). Poor treatment
outcomes were more common among anaemic patients
than non-anaemic patients (22% vs. 10%, P = 0.03)
(Table 3). HIV infection was not associated with poorer
TB treatment outcomes (20% vs. 13% for those with
HIV infection and no HIV infection, respectively,
P = 0.57).
All 242 patients were followed for a median of
20 months (IQR: 14 to 23 months) with a total of 4279
person-months. During this period, 35 poor treatment
outcomes occurred: 31 deaths and four treatment fail-
ures, resulting in eight poor outcomes per 1000 person-
months. The median time to a poor outcome was
5 months (IQR = 2–15 months), indicating poor out-
comes occurred during the intensive phase (i.e. the first
eight months of MDR-TB treatment).
Patients were lost to follow-up during the intensive
phase, after a median time of 7 months (IQR 4–
13 months), 14 (52%) within 8 months and seven (26%)
between 8–12 months. The reason loss to follow-up was
not recorded, but four (15%) developed side effects, with
one each developing nausea, vomiting, hypokalaemia and
psychosis. All of the lost-to-follow-up patients were
Figure 1 Schematic of survival and
treatment outcomes of the follow-up
patients included in the study
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Table 1 Baseline socio-demographic of MDR-TB patients stratified by treatment outcome in north-west Ethiopia from 2010 to 2015
Variables No. of patients (n = 242)
Treatment outcome
Event* (n = 35) Censored** (n = 207) P-value
Age at diagnosis (years) 0.1
<18 25 (10.3) 1 (2.9) 24 (11.6)
19–24 54 (22.3) 6 (17.1) 48 (23.2)
25–30 59 (24.4) 6 (17.1) 53 (25.6)
31–40 52 (21.5) 10 (28.6) 42 (20.3)
≥41 52 (21.5) 12 (34.3) 40 (19.3)
Sex 0.6
Male 147 (60.8) 20 (57.1) 127 (61.1)
Female 95 (39.3) 15 (42.9) 80 (38.6)
Zone of residence 0.9
North Gondar 123 (50.7) 21 (60.0) 102 (49.2)
South Gondar 48 (19.8) 6 (17.1) 42 (20.2)
Bahir Dar City 23 (9.5) 2 (5.7) 21 (10.1)
West Gojjam 14 (5.8) 2 (5.7) 12 (5.8)
East Gojjam 19 (8.0) 2 (5.7) 17 (8.2)
North Tigray 15 (6.2) 2 (5.7) 13 (6.2)
Marital status 0.6
Single 94 (38.8) 11 (31.4) 83 (40.1)
Married 105 (43.3) 19 (54.3) 86 (41.5)
Divorced 28 (11.5) 3 (8.6) 25 (12.0)
Widowed 5 (2.0) 1 (2.9) 4 (1.9)
Separated 10 (4.1) 1 (2.9) 9 (4.3)
Level of education
Unable to read and write 111 (45.8) 21 (60.0) 90 (43.5) 0.4
Primary 77 (31.9) 9 (25.7) 68 (32.8)
Secondary 32 (13.2) 3 (8.6) 29 (14.0)
Tertiary 22 (9.1) 2 (5.7) 20 (9.7)
Occupation 0.04
Government employee 22 (9.1) 1 (2.8) 21 (10.1)
Self-employed 33 (13.6) 2 (5.7) 31 (14.9)
Farmer 66 (27.3) 15 (42.8) 51 (24.6)
Housewife 27 (11.2) 6 (17.1) 21 (10.1)
Student 39 (16.1) 3 (8.6) 36 (17.4)
Daily labourer 41 (16.9) 8 (22.9) 33 (15.9)
Not recorded 14 (5.7) 0 14 (6.8)
Average monthly income
(ETB), Median (IQR)
997 (600–997) 997 (500–997) 997 (600–997) 0.6
Religion 0.3
Orthodox Christian 228 (94.2) 33 (94.3) 195 (94.2)
Muslim 12 (4.9) 1 (2.8) 11 (5.3)
Others 2 (0.8) 1 (2.8) 1 (0.5)
Treatment supporter 0.3
Parents 34 (14.0) 2 (5.7) 32 (15.5)
Children 22 (9.1) 4 (11.4) 18 (8.7)
Siblings 42 (17.4) 6 (17.1) 36 (17.4)
Other relative 42 (17.4) 9 (25.7) 33 (15.9)
Spouse 26 (10.7) 6 (17.1) 20 (9.7)
No supporter 58 (23.9) 6 (17.1) 52 (25.1)
Not recorded 18 (7.4) 2 (5.7) 16 (7.7)
The P-value was taken from the Pearson’s chi-square (v2) test or Fisher’s exact test, independent t test or Wilcoxon rank-sum (Mann–
Whitney) test. ETB, Ethiopian Birr; SD, standard deviation; IQR, interquartile range.
*Event in this study was either death or treatment failure; censored** was either cured, completed, transferred out, default, still on
treatment.
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taking a regimen containing cycloserine; more than one-
third (10, 37%) were from North Gondar Zone, and 21
(78%) were sputum smear positive.
The overall cumulative probability of survival at the
end of 6 months was 86% (95% CI: 85.9%, 92.9%) and
at the end of 24 months was 80% (95% CI: 70.1%,
Table 2 Baseline clinical characteristics of MDR-TB patients stratified by treatment outcome in north-west Ethiopia from 2010 to
2015
Variables No. of patients (n = 242)
Treatment outcome
Event* (n = 35) Censored** (n = 207) P-value
Site of the disease 0.8
Pulmonary 227 (93.8) 33 (94.3) 194 (93.7)
Extra pulmonary 15 (6.2) 2 (5.7) 13 (6.2)
BMI, mean (SD) 17.18  2.71 16.23  2.77 17.34  2.68 0.02
Previously treated for TB 0.4
Not treated (new) 17 (7.1) 5 (14.3) 12 (5.8)
Once 42 (17.5) 7 (20.0) 35 (17.1)
Twice 109 (45.4) 13 (37.1) 96 (46.8)
Three times 46 (19.1) 7 (20.0) 39 (19.0)
Four times and above 26 (10.9) 3 (8.6) 23 (11.2)
HIV status 0.2
Positive 51 (21.1) 10 (28.6) 41 (19.8)
Negative 191 (78.9) 25 (71.4) 166 (80.2)
Any comorbidity 0.2
None recorded 183 (75.6) 22 (62.9) 161 (77.1)
HIV 51 (21.1) 10 (28.7) 41 (19.8)
Diabetes mellitus 5 (2.0) 2 (5.7) 3 (1.4)
Congestive heart failure 1 (0.4) 0 1 (0.9)
Hypertension 1 (0.4) 0 1 (0.9)
Hepatitis 1 (0.4) 1 (2.9) 0
Initial regimen 0.5
Z, E, Cm, Lfx, Eto, Cs 121 (50.2) 15 (42.9) 106 (51.5)
Z, Cm, Lfx, Eto, Cs 120 (49.8) 20 (57.1) 100 (48.6)
Was the regimen modified 0.2
Yes 15 (6.2) 4 (11.4) 11 (5.3)
No 213 (88.0) 28 (80.0) 185 (89.4)
Not recorded 14 (5.8) 3 (8.6) 11 (5.31)
Taking vitamin B6 0.2
Yes 142 (58.92) 24 (68.57) 118 (57.28)
No 99 (41.08) 11 (31.43) 88 (42.72)
Initial sputum smear result 0.9
Positive 194 (80.2) 28 (80.0) 166 (80.2)
Negative 27 (11.2) 4 (11.4) 23 (11.1)
Not recorded 21 (8.7) 3 (8.6) 18 (8.7)
Initial culture result 0.1
Positive 131 (54.1) 16 (47.7) 115 (55.6)
Negative 23 (9.5) 1 (2.9) 22 (10.6)
Not recorded 88 (36.4) 18 (51.4) 70 (33.8)
Adverse effects 0.3
Yes 67 (27.7) 12 (34.3) 55 (26.6)
No 175 (72.3) 23 (65.7) 152 (73.4)
Haemoglobin (Hgb), mean (SD) 12.42  6.1 10.7  2.73 12.7  6.5 0.07
Alanine transaminase (ALT), median (IQR) 15.7 (11.2–22.2) 15.7 (11–34.3) 15.7 (11.8–22.2) 0.4
Aspartate transaminase (AST), median (IQR) 23.0 (17.4–32.8) 23 (17–33) 23 (20–32) 0.4
Creatinine, mean (SD) 0.6  0.2 0.6  0.2 0.6  0.2 0.9
Potassium (K), mean  SD 3.9  0.7 4.1  1.0 3.9  0.6 0.2
White blood cell count (WBC), mean  SD 6700 (5300–8200) 6700 (5300–7200) 6700 (5300–8400) 0.6
The P-value was taken from the Pearson’s chi-square (v2) test or Fisher’s exact test, independent t-test or Wilcoxon rank-sum (Mann–
Whitney) test. BMI, body mass index; ETB, Ethiopian Birr; SD, standard deviation; IQR, interquartile range; Cm, capreomycin; Lfx,
levofloxacin; Pto, prothionamide; Eto, ethionamide; Z, pyrazinamide; (Eto); Cs, cycloserine.
*Event in this study was either death or treatment failure; censored**was either cured, completed, transferred out, default, still on treatment.
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87.0%). The median survival time or the survival time at
which the cumulative survival function is equal to 0.5
could not be determined because the largest number of
observations was censored (Figure 2). Anaemic patients
had a shorter survival time than non-anaemic patients
(P = 0.004). The cumulative probability survival of anae-
mic patients at the end of 24 months was 76% (95% CI:
64%, 84%), and the cumulative probability survival of
non-anaemic patients at the end of 24 months was 85%
(95% CI: 73%, 92%) (Figure 3).
Trends of MDR-TB treatment outcomes
The number of patients who started MDR-TB treatment
at Gondar University Hospital increased each year
between 2010 and 2013. However, after 2013, the num-
ber of MDR-TB patients enrolled at Gondar University
Hospital decreased. Proportionally, the poor treatment
outcome rate decreased as the number of MDR-TB cases
enrolled to the treatment centre increased and increased
as the number of MDR-TB cases decreased (correlation
coefficient: r = 0.59). Generally, the poor treatment
outcome rate increased over time since 2012 (Figure 4).
Patients who started treatment between 2010 and 2012
showed better treatment outcomes (6%/PY) than patients
who started treatment between 2013 and 2015 (12%/
PY). Between 2010 and 2012, there were nine deaths but
no treatment failures, with a total observation time of
1713 person-months, whereas between 2013 and 2015,
there were 21 deaths and four treatment failures, with a
total observation time of 2566 person-months. Thus, the
incidence rate for the period 2010–2012 was 6%/PY; for
the period 2013–2015, it was 12%/PY, giving an
incidence rate ratio (IRR) of 2 for 2013–2015 relative to
2010–2012. The proportion of patients who had previ-
ously been treated with first-line antituberculosis drugs
more than four times increased from 3% in 2010 to 34%
in 2013.
Predictors of poor MDR-TB treatment outcomes
In bivariate analysis, low haemoglobin levels (i.e. anae-
mia), taking vitamin B6, being prescribed an initial regi-
men with Z+E+Cm+Lfx+Eto+Cs (compared with
Z+Cm+Lfx+Eto+Cs) and being a farmer or a daily
labourer were significantly associated with time to poor
treatment outcome (Table 4). However, in multivariate
analyses, being a farmer and being anaemic were the only
independent predictors of time to poor treatment outcome
(Table 5). Those who had low haemoglobin levels (i.e.
patients with anaemia) were more than two times at risk
to have a poor treatment outcome at any time than those
who had normal haemoglobin levels [AHR = 2.2; 95%
CI: 1.0, 4.9]. Similarly, farmers were more than four times
at risk to have a poor treatment outcome at any time than
employees [AHR = 4.2; 95% CI: 1.1, 15.9].
Discussion
This study was designed to assess treatment outcomes
and determine predictors of time to poor treatment out-
comes in the first cohort of MDR-TB patients in north-
west Ethiopia. We found that the overall cumulative
probability of treatment success (i.e. having an outcome
of cured or treatment completed) at the end of the treat-
ment (24 months) was 80% (95% CI: 70%, 87%),
Table 3 Treatment outcomes of patients with multidrug-resistant tuberculosis among HIV-infected and HIV-uninfected patients, and
anaemic and non-anaemic patients, north-west Ethiopia
Treatment outcome
Total patients
N = 242 (%)
Patients’ HIV status Anaemia**
Infected = 51 (%) Uninfected = 191 (%) Anaemia = 90 (%) No anaemia = 152 (%)
Successful treatment
Cured 131 (54.1) 29 (56.9) 102 (53.4) 44 (48.9) 87 (57.2)
Completed 23 (9.5) 3 (5.9) 20 (10.5) 6 (6.7) 17 (11.2)
Not evaluated
Alive* 20 (8.2) 3 (5.9) 17 (8.9) 8 (8.9) 12 (7.9)
Transferred out 6 (2.5) 1 (2.0) 5 (2.6) 1 (1.1) 5 (3.3)
Lost to follow-up 27 (11.1) 5 (8.8) 22 (11.5) 11 (12.2) 16 (10.5)
Poor outcome
Died 31 (12.8) 9 (17.6) 22 (11.5) 17 (18.9) 14 (9.2)
Treatment failure 4 (1.6) 1 (2.0) 3 (1.6) 3 (3.3) 1 (0.6)
*Those who were on treatment and alive during the study period; **Anaemia is defined as having a haemoglobin concentration less
than 120 g/l.
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which is similar to other resource-constrained countries
such as Egypt and India [20, 21] and also high-income
countries such as Switzerland (76%) [22], the United
Kingdom (70.60%) [23] and the United States of America
(78%) [24]. This indicates that good treatment outcomes
can be achieved in resource-limited settings. The WHO
target of 75% treatment success by 2015 has been met in
this cohort [10]. This encouraging outcome in north-west
Ethiopia may be due to several reasons, related to the
study population and the treatment programme. The
patients in our study were generally young, with few seri-
ous comorbidities, and they were treated with individu-
alised regimens with a combination of five or six effective
drugs. Further, all patients were admitted to the hospital
during the intensive phase of treatment and received
directly observed therapy. In addition, in the continuation
phases of treatment, patients were followed and traced
using several strategies: health professionals from the
treatment centres visited the patients every month; the
patients were appointed monthly to visit the treatment
Event 20 4 7 3 1 0 0
censored 17 8 27 112 40 2 1
Survival (%) 91.4 90 86 84 80 80 80
95% CI (%) 87, 94 85, 93 81, 90 78, 88 70, 87 70,   
87
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Figure 2 Kaplan–Meier curve showing
the probability survival of MDR-TB
patients since the commencement of
treatment to end of the treatment follow-
up at Gondar University Hospital MDR-
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Figure 3 Kaplan–Meier probability of
survival curve for anaemic and non-
anaemic MDR-TB patients at Gondar
University Hospital MDR-TB Treatment
Centre, north-west Ethiopia.
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initiation site; treatment supporters were assigned from
the patient’s family to assist the patient with directly
observed therapy; and food baskets were provided regu-
larly for the patients.
Despite the high treatment success rate, the propor-
tion of people who died or who failed treatment
increased over time. We observed that patients who
started treatment between 2010 and 2012 had better
treatment outcomes than patients who started treatment
between 2013 and 2015. This could be due to the fact
that as the number of patients with MDR-TB has
increased over time and more MDR-TB treatment cen-
tres were opened in other areas, the emphasis given to
this treatment centre in terms of resource allocation and
quality of service provided to each individual patient
may have declined. Although it requires further investi-
gation, this may also be related to a change in suscepti-
bility patterns. Of concern is that our results showed
that patients who were previously treated with first-line
anti-TB drugs more than four times increased from 3%
in 2010 to 34% in 2013.
Another important finding was that both poor treat-
ment outcomes (death or treatment failure) and loss to
follow-up mainly occurred in the first 6 months of MDR-
TB treatment (i.e. during the intensive phase). There are
several possible explanations for this result. Firstly,
adverse effects from second-line drugs may be most acute
during the intensive phase, thereby interrupting treatment
[25]. Secondly, a diagnosis of MDR-TB (and the prospect
of taking treatment for 2 years and being hospitalised for
6 months) may create psychosocial problems that led to
a poor prognosis, particularly in the early phase of the
treatment [26]; and thirdly, late diagnosis of MDR-TB
might be responsible, as the majority of our patients were
treated with first-line antituberculosis drug several times.
This finding suggested that for further improvement of
the treatment outcome, early diagnosis of drug-resistant
TB is paramount and then effective treatment and man-
agement should follow as early as possible before the
patient’s compliance declines as a result of fatigue with
the first-line anti-TB drug treatment without any per-
ceived benefit. It is also necessary to provide psychologi-
cal counselling for the patients at the time of MDR-TB
diagnosis and to closely monitor all patients for adverse
drug effects, especially at the early stages of treatment.
Anaemia was one of the factors associated with poor
MDR-TB treatment outcomes in our study. Patients who
were anaemic were more than two times more likely to
have a poor treatment outcome than patients who were
non-anaemic. This might be related with late presentation
of the patients. Previous studies have also shown that
anaemia with or without iron deficiency at TB diagnosis
is associated with an increased risk of death [27–29]. In
addition to being anaemic, the majority (72%) of the
patients in our study were underweight (BMI < 18.5 kg/
m2) and had low average monthly income (around 1.5
USD a day). Early diagnosis and treatment of MDR-TB
patients is also suggested to improve the treatment out-
come of the patients.
We have also found that farmers were at a higher risk
of poor treatment outcome than other types of employ-
ees. This could be due to non-adherence to therapy. In
Year 2010 Year 2011 Year 2012 Year 2013 Year 2014 Year 2015
Total MDR-TB patients 8 27 42 66 35 11
Succeful treatmetnt outcome 75 85.19 92.86 84.85 68.57 54.55












Figure 4 Trends of the number of MDR-TB patients, successful treatment outcome and poor treatment outcome at Gondar University
Hospital MDR-TB Treatment Centre, north-west Ethiopia from 2010 to 2015.
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<18 years 1/21 (4.7) 1.00 –
19–39 years 19/115 (16.5) 3.2 (0.4, 24.0) 0.25
>40 years 15/53 (28.3) 6.0 (0.8, 45.4) 0.08
Sex
Male 20/116 (17.2) 1.00 –
Female 15/75 (20.5) 1.2 (0.6, 2.4) 0.54
Job
Employee 3/42 (7.1) 1.00 –
Farmer 15/51 (29.4) 2.7 (1.4, 16.4) 0.01
Housewife 6/23 (26.0) 4.2 (1.0, 16.7) 0.04
Labourer 8/34 (23.5) 3.6 (0.9, 13.6) 0.06
Student and others 3/39 (18.5) 1.2 (0.2, 5.8) 0.85
Previous TB treatment
New 5/15 (33.3) 2.6 (0.9, 7.8) 0.07
Once 7/27 (25.9) 1.8 (0.7, 4.8) 0.22
Twice 13/82 (15.8) 1.1 (0.5, 2.5) 0.85
Three and above 10/64 (15.6) 1.00 –
HIV status
Positive 10/42 (38.8) 1.5 (0.7, 3.0) 0.30
Negative 25/147 (17.0) 1.00 –
BMI
<18.5 kg/m2 27/135 [19] 1.4 (0.6, 3.0) 0.41
≥18.5 kg/m2 8/54 (14.8) 1.00 –
Initial regimen
Z+E+Cm+Lfx+Eto+Cs 15/108 (13.8) 2.1 (1.0, 4.1) 0.03
Z+Cm+Lfx+Eto+Cs 20/80 [24] 1.00 –
Taking vitamin B6
Yes 24/89 (12.3) 1.00 0.03
No 11/99 (24.2) 0.4 (0.2, 0.9) –
Haemoglobin
Non-anaemic 15/119 (12.6) 1.00 –
Anaemic** 20/70 (28.5) 2.6 (1.3, 5.0) 0.006
Alanine transaminase (ALT)
Normal 31/175 (17.7) 1.00 –
Elevated 4/14 (28.5) 1.7 (0.6, 4.9) 0.31
Aspartate transaminase (AST)
Normal 30/151 (19.9) 1.00 –
Elevated 5/38 (13.1) 0.6 (0.2, 1.6) 0.35
Potassium
Normal 33/183 (18.0) 1.00 –
Elevated 2/6 (33.3) 2.1 (0.5, 8.9) 0.30
Creatinine (mean) 0.65/0.62 1.6 (0.4, 7.0) 0.51
WBC count
Normal 26/148 (17.5) 1.00 –
Low 7/31 (22.5) 1.23 (0.5, 2.9) 0.57
High 2/10 (20.0) 1.0 (0.2, 4.5) 0.92
Lost to follow-up, still on treatment and transferred out patients were excluded from
the bivariate Cox proportional hazard model. Other socio-demographic and clinical
variables mentioned in Table 1 were tested but not included in this table because their
P-value was greater than 0.5.
*Values are number of poor treatment outcome/total number of patients (%).
**Anaemia was defined as having a haemoglobin concentration of less than 120 g/l.
Table 4 Bivariate Cox proportional haz-
ards regression analysis of predictors for
time to poor treatment outcome (mortal-
ity or treatment failure) among 189
MDR-TB patients
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north-west Ethiopia, previous studies have demonstrated
that farmers have delayed healthcare-seeking behaviour,
live far from referral hospitals where MDR-TB treatment
is offered, have a low socio-economic status and have
poor knowledge regarding tuberculosis [30–33]. Further
decentralisation of health services may assist those living
far from referral hospitals to access and remain on
MDR-TB treatment. There may be many other reasons
that farmers are at higher risk of poor TB treatment out-
comes when compared to other occupations, in addition
to confounding factors that we were not able to measure.
We acknowledge that farmers may die from causes other
than tuberculosis and may have different mortality pat-
terns when compared to other types of employees. We
found no difference in poor treatment outcomes accord-
ing to HIV status. Other studies have also noted this
finding [34, 35]. This result is encouraging for those
managing MDR-TB services and provides reassurance for
patients and advocates who may experience stigma when
diagnosed with both diseases.
There were several limitations to this study. Firstly, this
study was based on secondary data obtained from patients’
medical records and registers. Therefore, potentially
important variables such as presence of cavitation on chest
radiograph and behavioural factors were not assessed to
determine their relationship with poor treatment out-
comes. Secondly, in this study those patients who had doc-
umented evidence of completion were counted as having a
successful treatment outcome, whereas they may have
undetected failure of therapy. This may lead to overestima-
tion of the treatment outcome rate in our study, although
completed cases in general were few in number (less than
10%). Finally, as the treatment centre was only opened
recently, sample size and number of years of data were
small and a longer follow-up period will be required to
assess longer-term trends in treatment outcomes.
Conclusions
The findings from this study demonstrate that good out-
comes for MDR-TB patients can be achieved in a
resource-constrained and high TB-burden country. How-
ever, poor treatment outcomes have gradually increased
overtime. Being a farmer and being anaemic were associated
with poor treatment outcomes. This could be confounded
by unmeasured factors, and it would be beneficial to assess
other risk factors that might affect treatment outcomes, such
as co-infection with malaria, poverty and other socio-eco-
nomic and biological risk factors.
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